Group 1 - The medical beauty sector increased by 3.9% on February 3, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 147.57, up 4.56%, and Huaxi Biological at 48.81, up 3.45% [1] Group 2 - The medical beauty sector saw a net inflow of 72.0481 million yuan from main funds, while retail funds experienced a net outflow of 41.6043 million yuan [1] - Ai Meike had a net inflow of 85.9952 million yuan from main funds, but retail funds saw a net outflow of 38.6841 million yuan [2] - Huaxi Biological experienced a net outflow of 10.4367 million yuan from main funds, with a net inflow of 14.2989 million yuan from speculative funds [2]

Group 1 - The major indices collectively rose on February 3, with the National Bio-Medical Index (399441) increasing by 1.15%. Notable stocks included Zhaoyan New Drug and Aimeike, both rising over 4%, while Tigermed and Huaxi Biological increased by over 3%, and Kailaiying rose nearly 3% [1] - The Bio-Medical ETF (159859) had a trading volume exceeding 65 million yuan, ranking first among its peers. The net inflow for this ETF on the previous trading day (February 2) was 67.29 million yuan, and it has seen continuous net inflows over the past 10 days, accumulating over 440 million yuan [1] - The latest circulating share of the Bio-Medical ETF is 9.569 billion shares, with a total market size of 3.674 billion yuan, making it the largest in its category [1] Group 2 - The Shanghai Municipal Government's work report emphasized the need to deepen the construction of an international economic center, focusing on modern industrial systems and supporting sectors such as bio-medicine, integrated circuits, and artificial intelligence [2] - According to Zhongtai Securities, the pharmaceutical market opportunities are expected to revolve around thematic opportunities, with potential performances in brain-computer interfaces, AI healthcare, and small nucleic acids. There is also a strategic emphasis on the raw material drug sector, which is at a bottom range and may see a mid-term positive cycle due to rising chemical prices and new business additions [2]

2026年1月29日，新浪财经、第一财经与古井贡酒·年份原浆古20共同携手举办的"为中国经济点赞——企业家之夜"在北京正大中心举行。 这不仅仅是一场年度荣誉盛宴，更是一扇观察中国经济韧性、多元动力与未来方向的窗口。透过企业家们的感言、洞察与愿景，我们得以窥见中国经济在承 压前行中，那些坚实而蓬勃的驱动力。 基石的力量，传统产业的升级与自信 当紫金矿业创始人陈景河在回顾企业成长视频时悄然落泪，全场为之动容。这泪水，不仅是个体创业艰辛与荣耀的抒发，更是中国基础产业在全球竞争中逆 势崛起的缩影。 陈景河直言，西方公司曾控制最优质的矿业资源，但紫金凭借完整的技术能力、强大的探矿能力和每一位艰苦卓绝、富有奉献精神的紫金人，实现了"所向 披靡"。他从一个县级小企业起步，到将海外黄金板块成功分拆上市，市值瞩目，其自信宣言——"现在想不发财都很难"，背后是中国矿业企业在技术、管 理、国际化运营上累积的深厚内功。 智谱董事长刘德兵谈及其AGI（通用人工智能）愿景："让机器像人一样思考"，代表了在人工智能基础层追求终极境界的雄心。小马智行彭军则通过实时连 线无人驾驶车，展现了十年专注Robotaxi，让未来出行更安全高效的务实路 ...

Core Viewpoint - The silver economy in China is experiencing significant growth, with projections indicating that the market size will exceed 16 trillion yuan by 2030, driven by the evolving consumption habits of the new generation of elderly consumers [1][2]. Group 1: Market Overview - In 2019, the market size of China's silver economy reached 4.3 trillion yuan, growing to 7.1 trillion yuan in 2023, and is expected to further increase to 8.3 trillion yuan in 2024. By 2030, the overall market size is anticipated to surpass 16.2 trillion yuan, indicating substantial potential for the silver economy [2]. - The new generation of elderly consumers exhibits significant differences in wealth levels, family structures, and consumption habits compared to previous generations, prompting companies to adapt their business strategies to meet these new consumer demands [2]. Group 2: Retail Sector - Leading retail companies such as Bailian Group and Chongqing Department Store are developing business models tailored to the purchasing habits and preferences of elderly consumers, addressing both social and purchasing needs [2]. - Supermarket chains like Hema and Yonghui are enhancing their product offerings and introducing "silver community canteens" to increase foot traffic and conversion rates among elderly shoppers [2]. Group 3: Gold and Jewelry Sector - Middle-aged and elderly consumers have historically been the primary market for gold products, driven by a focus on value preservation and brand loyalty. Companies like Caibai and Lao Fengxiang are leveraging their strong brand foundations to cater to this demographic [3]. - These companies are enhancing their product offerings through collaborations and improving customer loyalty via robust after-sales services, positioning themselves to benefit from the expanding customer base [3]. Group 4: Beauty and Personal Care Sector - The proportion of elderly consumers in the beauty and medical aesthetics markets is steadily increasing, with significant growth potential in both volume and pricing, similar to trends observed in mature overseas markets [4]. - Leading companies with strong upstream raw material capabilities and comprehensive solutions, such as Huaxi Biological and Aimeike, are expected to benefit from the rising sales among elderly consumers [4]. - Companies focused on elderly care, like Kelaibao, are also poised to gain from the expanding target audience in the personal care sector [4].

Group 1 - On February 2, Huaxi Bio's stock rose by 5.24%, with a trading volume of 562 million yuan [1] - The financing data shows that on the same day, Huaxi Bio had a financing purchase amount of 68.0048 million yuan and a net financing purchase of 3.4537 million yuan [1] - As of February 2, the total balance of margin trading for Huaxi Bio was 554 million yuan, with a financing balance of 550 million yuan, accounting for 2.42% of the circulating market value [1] Group 2 - Huaxi Bio, established on January 3, 2000, and listed on November 6, 2019, operates in the field of microbial fermentation and cross-linking technology, focusing on bioactive materials for health [2] - The company's revenue composition includes 40.34% from skin science innovation, 29.76% from medical terminal products, and 27.70% from raw materials [2] - For the period from January to September 2025, Huaxi Bio reported a revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit of 252 million yuan, down 30.29% year-on-year [2] Group 3 - Since its A-share listing, Huaxi Bio has distributed a total of 1.138 billion yuan in dividends, with 528 million yuan distributed in the last three years [3] - As of September 30, 2025, major shareholders of Huaxi Bio have seen a reduction in holdings, with the top ten circulating shareholders decreasing their shares [3]

Investment Rating - The report maintains a "Recommended" investment rating for the beauty and personal care industry [5][26]. Core Insights - Betaini Group's brand Winona has officially entered the Middle East market, expanding its overseas footprint by opening its first offline store in Doha Mall, Qatar, marking it as the first Chinese functional skincare brand registered in Qatar [5][24]. - The report highlights the global development strategy of companies in the medical beauty sector, emphasizing a transition from single product output to a systematic compliance layout and the value output of "Chinese solutions" [5][26]. - The report suggests focusing on companies with core raw material technology advantages and a full industry chain matrix, such as Marubi Biotechnology, Huaxi Biological, and Juzhi Biological [5][26]. Summary by Sections Recent Market Performance - From January 26 to January 30, 2026, the Shenwan Beauty and Personal Care Index decreased by 3.92% [13]. - The top five gainers in the sector included companies like Four Seasons Medicine and Yisi Health, while the biggest losers included Lafang Cosmetics and Shanghai Jahwa [13]. Industry News - Time安生物's siRNA weight loss drug targeting ALK7 has achieved global simultaneous submission for clinical trials, showcasing the company's global development strategy [18][19]. - The customs authority has introduced nine measures to support the development of the beauty industry, focusing on building Guangzhou as a global cosmetics manufacturing and consumption center [20]. Key Company Announcements - Baiya Co., Ltd. announced plans for share reduction by major shareholders, while Jeya Co., Ltd. plans to recognize asset impairment losses to reflect its financial status accurately [21][22]. Weekly Insights - The opening of Winona's store in Qatar is a significant step in the brand's globalization strategy, receiving recognition from local medical and retail sectors [24][25]. - The report emphasizes the importance of systematic compliance capabilities and clinical validation in the development of medical beauty enterprises [26]. Investment Recommendations - The report recommends focusing on companies with strong R&D capabilities and market positioning, such as Betaini and Aimeike, while also considering traditional brands that are actively transforming [26].

Investment Rating - The report maintains an "Outperform the Market" rating for the industry [2][48]. Core Insights - The silver economy in China is rapidly expanding, with the market size projected to grow from 4.3 trillion yuan in 2019 to 7.1 trillion yuan in 2023, and further to 8.3 trillion yuan in 2024. By 2030, the market is expected to exceed 16.2 trillion yuan, indicating significant growth potential [3][5][42]. - The new generation of elderly consumers, primarily those born in the 1960s and 1970s, exhibit different consumption habits compared to previous generations, focusing more on enjoyment and quality rather than just practicality [19][34]. Summary by Sections Market Size and Growth - The silver economy market size in China reached 4.3 trillion yuan in 2019, growing to 7.1 trillion yuan in 2023, and is expected to reach 8.3 trillion yuan in 2024. By 2030, it is projected to surpass 16.2 trillion yuan, with a compound annual growth rate (CAGR) of approximately 11.5% from 2025 to 2030 [3][5][42]. Consumer Behavior - The new elderly demographic is characterized by higher education levels and disposable income, leading to a shift in consumption from "saving" to "enjoyment." They prioritize health, quality, and emotional experiences in their purchasing decisions [19][25][34]. - Online shopping is becoming increasingly popular among the elderly, with 1.56 billion users aged 60 and above, representing 14.1% of total internet users. This demographic is significantly influenced by peer recommendations and social media [20][24]. Industry Trends - Retailers are adapting to the needs of elderly consumers by creating shopping environments that combine social interaction with purchasing. Companies like Bailian and Chongqing Department Store are developing tailored business models to cater to the preferences of this demographic [3][26][42]. - In the jewelry sector, older consumers remain a key market, with a focus on investment and brand loyalty. Companies like Caibai and Laofengxiang are enhancing their offerings to meet the demands of this consumer group [4][43]. Beauty and Healthcare - The beauty and healthcare market for the elderly is expanding, with a notable increase in the consumption of skincare and medical beauty services. The market for beauty products among consumers aged 50 and above is growing, with significant sales increases reported [34][37]. - The medical beauty sector is also expected to grow, with older consumers increasingly seeking anti-aging treatments and comprehensive care solutions [39][40]. Policy Support - Recent government policies are aimed at promoting the silver economy, emphasizing the importance of addressing the needs of the elderly population and fostering the development of related industries [9][12].

Performance Overview - The company forecasts a net profit of between 270 million and 320 million for 2025, representing a year-on-year increase of 55% to 84%, with Q4 2025 net profit expected to be between 20 million and 70 million, indicating a turnaround from losses [1] - The annual non-GAAP net profit is projected to be between 170 million and 220 million, reflecting a year-on-year growth of 56% to 102%, with Q4 2025 non-GAAP net profit expected to range from -20 million to 30 million, indicating a reduction in losses or a turnaround [1] Commentary and Recommendations - In 2025, the chairman and general manager will lead the team back to the front lines, making adjustments to organizational structure, strategic planning, and product structure [2] - The company has improved operational efficiency and optimized operating costs, with a significant reduction in sales expense ratio by over 30% year-on-year, and a 6.8 percentage points decrease in the sales expense ratio for the first three quarters [2] - The company continues to deepen research in sugar biology and cell biology, laying a solid foundation for long-term development [2] - For 2026, the company is expected to continue improving operations, with stable growth in raw material business and strengthened competitive barriers due to ongoing optimization of production and research integration [2] - The medical terminal business saw a positive growth rate in Q3 2025, with a year-on-year revenue increase of 14.5%, and this positive trend is expected to continue into 2026 with improved channel structure and increased direct sales ratio [2] - The skin science innovation transformation business is entering a deep reform phase, focusing on fee structure, organizational structure, and strategic adjustments [2] - Profit forecasts remain unchanged, with expected net profits of 310 million, 530 million, and 600 million for 2025-2027, representing year-on-year increases of 76.4%, 72%, and 13.3% respectively, with EPS of 0.64 yuan, 1.10 yuan, and 1.24 yuan, corresponding to PE ratios of 70x, 41x, and 36x, maintaining a "range operation" investment recommendation [2]

Core Viewpoint - The medical beauty sector experienced a rise of 2.68% on February 2, with Huaxi Biological leading the gains, while the overall market indices, Shanghai Composite and Shenzhen Component, saw declines of 2.48% and 2.69% respectively [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4015.75, down 2.48% [1] - The Shenzhen Component Index closed at 13824.35, down 2.69% [1] - The medical beauty sector stocks showed varied performance, with Huaxi Biological rising by 5.24% to a closing price of 47.18 [1] Group 2: Stock Details - Huaxi Biological (688363) had a trading volume of 118,200 shares and a transaction value of 562 million yuan [1] - Aimei Ke (300896) closed at 141.14, up 1.01%, with a trading volume of 47,500 shares and a transaction value of 683 million yuan [1] - ST Meigu (000615) closed at 3.08, up 0.33%, with a trading volume of 115,100 shares [1] - Jinbo Biological (920982) closed at 214.89, down 2.94%, with a trading volume of 9,949 shares and a transaction value of 217 million yuan [1] Group 3: Fund Flow Analysis - The medical beauty sector saw a net inflow of 100 million yuan from main funds, while retail investors experienced a net outflow of 59.89 million yuan [1] - Aimei Ke had a main fund net inflow of 55.54 million yuan, but a net outflow of 33.36 million yuan from retail investors [2] - Huaxi Biological experienced a main fund net inflow of 44.73 million yuan, with retail investors showing a net outflow of 27.92 million yuan [2]

Core Viewpoint - Huaxi Biological Technology Co., Ltd. is expected to see significant profit growth in 2025, driven by operational efficiency improvements and strategic adjustments, despite a recent decline in stock price from a peak of 313 yuan to around 50 yuan per share [1][9]. Financial Performance - The company anticipates a net profit attributable to shareholders of 270 million to 320 million yuan for 2025, representing a year-on-year increase of 54.93% to 83.63% [3][11]. - The net profit excluding non-recurring gains is projected to be between 167 million and 217 million yuan, with a growth rate of 55.68% to 102.29% [3][11]. - The low base from 2024, where the total profit was 213 million yuan and net profit was 174 million yuan, contributes to the substantial growth figures [3][11]. Business Strategy and Operations - The core driver of the expected profit growth is the steady improvement in the main business, focusing on "agile management and growth efficiency" [3][11]. - The company is optimizing its organizational structure, integrating overlapping functions, and upgrading operational models to shift from "scale expansion" to "quality growth" [4][12]. - Management expenses are expected to decrease by over 10% year-on-year, while sales expenses are projected to drop by more than 30% [4][12]. Research and Innovation - Huaxi Biological is enhancing its research capabilities in glycoscience and cell biology, focusing on cutting-edge studies related to extracellular matrix regulation and aging intervention [4][12]. - The company is leveraging AI technology to optimize business processes and improve operational efficiency across the supply chain and management [4][12]. Shareholder Activity - Recently, a long-term shareholder, Guoshou Chengda, reduced its stake by 2.00%, selling approximately 9.63 million shares for about 428 million yuan [5][13]. - Following the reduction, Guoshou Chengda's holdings decreased to 4.01%, exiting the top five shareholders [5][13]. Future Outlook - Analysts expect continued improvement in the company's operations in 2026, with stable growth in raw material business and positive trends in medical terminal business [6][13]. - The skin science innovation sector is entering a reform phase, focusing on structural adjustments [6][13].